An interventional study of Biopsy in Melanoma and Pancreas Cancer, sponsored by Amsterdam UMC, location VUmc. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Basic science
Among 170 studies in Melanoma with a site in Netherlands — 29 open to participants now, 49 under way, 13 of them phase 3. Melanoma · Netherlands.
Among the 170 studies in Melanoma with a site in Netherlands, this one is the 78th largest by planned enrollment of the 157 interventional ones that give a count, is one of 11 that started in 2023, is one of 17 with no phase, reaches primary completion later than 24 of the 48 other live ones, and was the 150th registered.
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
Browse Melanoma studies →29 of the 170 studies in Melanoma with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Pfizer · Sites in Netherlands, United States, France and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in Netherlands, United States, Belgium
Ages 18+
IDEAYA Biosciences · Sites in Netherlands, United States, Australia and 18 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
170 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 60 · Phase 4 4
First in 1995; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 40 across 2,649 interventional studies indexed under Melanoma.
Median enrollment 180 across the 157 interventional studies, 142 across the 12 observational. Of the 107 that completed or were terminated, 56 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 170 have an industry lead sponsor. The 10 most frequent:
Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.
Amsterdam UMC, location VUmc has 3 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Melanoma with a site in Netherlands that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
| NCT07796594Amsterdam UMC, location VUmcIntegration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 170 studies in Melanoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this investigator-initiated tumour profiling study is to analyse the relation between genomic alterations and the tumour immune contexture in patients with advanced melanoma and pancreatic cancer with resistance to (immuno)therapy, aiming to identify targets and approaches for future (combination) treatment. The main endpoint of this study is the number of patients for whom both tumour WGS and immune profiles could be adequately obtained.
The co-primary endpoint is the frequency of "inflamed" vs "immune excluded/desert" tumours (based on tumour infiltrating immune cells) in patients with i) NRAS/KRAS mutant vs wild-type tumours and ii) High vs low mutational tumour load.
Participants will undergo an extra tumour biopsy procedure and venepuncture once during a tumour biopsy procedure done performed as part of standard treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of locally advanced or cutaneous/mucosal melanoma or pancreatic cancer, meeting the following characteristics:
a. Melanoma i. Patients with proven locally advanced or metastatic melanoma (stage IV), with intrinsic or acquired resistance to treatment with immune checkpoint inhibition (anti-PD1 antibody +/- ipilimumab) ii. Patients with locoregional or distant recurrence either during, or within 3 months after completion or discontinuation of (neo) anti-PD1-based immunotherapy for stage III melanoma.
b. Pancreatic cancer i. Patients with histologically proven metastatic pancreatic cancer with progression under or after standard chemotherapy with FOLFIRINOX.
Exclusion Criteria:
- Patients with or locally advanced lesions which are not considered to be technically and/or safely biopsied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo tumour biopsy and blood draw once
Procedure: Biopsy
Participants will undergo an extra tumour biopsy procedure and venepuncture once.
Number of tumour WGS and immune profiles
number of patients for whom both tumour WGS and immune profiles could be adequately obtained
Time frame: through study completion, an average of 1 year
"inflamed" vs "immune excluded/desert" tumours
The co-primary endpoint is the frequency of "inflamed" vs "immune excluded/desert" tumours (based on tumour infiltrating immune cells) in patients with i) NRAS/KRAS mutant vs wild-type tumours and ii) High vs low mutational tumour load
Time frame: through study completion, an average of 1 year
The percentage of patients with evaluable tumour DNA, RNA and (tissue and peripheral) immune profiles
Time frame: Through study completion, an average of 2 year
The frequency of (potentially) actionable genomic alterations
Time frame: Through study completion, an average of 2 year
Differences between the post-immunotherapy and post-chemotherapy mutational/RNA-profiles with pre-treatment profiles (e.g. copy numbers, mutational load, genetic aberrations) of a similar cohort of patients who participated
Time frame: After study completion, an average of 2 year
The relation between tumour and peripheral immune profiles and changes over time in patients with intrinsic vs acquired resistance to immune checkpoint inhibition
Time frame: After study completion, an average of 2 year
The percentage of patients with melanoma with evaluable (phospho)proteomic profiles
Time frame: After study completion, an average of 2 year
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
Of 219 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 41 months is close to that.
Counting every sponsor, half of 227 studies reached it within 38 months; a quarter within 20 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amsterdam UMC, location VUmc →